Ulcerative Colitis Celgene’s Therapy Ozanimod Shows Promising Results in Phase 2 Trial

Ulcerative Colitis Celgene’s Therapy Ozanimod Shows Promising Results in Phase 2 Trial
Celgene Corporation, a biopharmaceutical company focused on the development of innovative therapies for cancer and immune-inflammatory related diseases, recently announced the results of the "maintenance phase" of its Phase 2 clinical trial TOUCHSTONE, assessing the company’s investigational drug Ozanimod in patients with ulcerative colitis. The results were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Honolulu, Hawaii. Ozanimod (RPC1063) is a sphingosine 1-phosphate 1 and 5 receptor modulator under development for conditions like relapsing multiple sclerosis and inflammatory bowel disease (IBD), including ulcerative colitis, a chronic, relapsing disorder triggered by an abnormal immune response that induces a long-lasting inflammation in the mucosa of the large intestine. It is estimated that 1 in every 402 individuals in North America suffer from ulcerative colitis. Modulators of S1P receptor are thought to interfere with the immune response of lymphocytes (a type of white blood cell), sequestering them within lymph nodes and preventing them from participating and contributing to autoimmune reactions. The randomized, double-blind, placebo-controlled TOUCHSTONE Phase 2 trial assessed the safety and efficacy of Ozanimod in 197 patients with moderate to severe active ulcerative colitis for a period of 8 weeks (induction phase). Participants who achieved a clinical response during this period (103 patients) continued their treatment up to week 32. Previously, the team reported that a significant proportion of patients achieved remission at week 8, meeting the trial’s primary endpoint. Researchers reported that after 32 weeks of treatment
Subscribe or to access all post and page content.